[1]李 峰,魏 群,周国雄,等.髓样细胞白血病-1基因 在原发性肝癌组织中的表达及临床意义[J].现代检验医学杂志,2016,31(03):69-72.[doi:10.3969/j.issn.1671-7414.2016.03.019]
　LI Feng,WEI Qun,ZHOU Guo-xiong,et al.Expression and Significance of Mcl-1 Gene in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):69-72.[doi:10.3969/j.issn.1671-7414.2016.03.019]
点击复制

髓样细胞白血病-1基因 在原发性肝癌组织中的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年03期
页码:
69-72
栏目:
论著
出版日期:
2016-06-15

文章信息/Info

Title:
Expression and Significance of Mcl-1 Gene in Hepatocellular Carcinoma
文章编号:
1671-7414(2016)03-069-05
作者:
李 峰; 魏 群; 周国雄; 黄东凤; 张 弘
南通大学附属医院消化病研究室,江苏南通 226001
Author(s):
LI Feng; WEI Qun; ZHOU Guo-xiong; HUANG Dong-feng; ZHANG Hong
Department of Gastroenterology, Affiliated Hospital of Nantong University,Jiangsu Nantong 226001,China
关键词:
髓样细胞白血病-1基因;  原发性肝癌;  肝硬化;  逆转录聚合酶链反应;  蛋白质印迹法;  免疫组织化学
分类号:
R735.7; R730.43
DOI:
10.3969/j.issn.1671-7414.2016.03.019
文献标志码:
A
摘要:
目的 探讨髓样细胞白血病-1(myeloid cell leukemia-1,Mcl-1)基因及蛋白在原发性肝癌和肝硬化组织中的表达及临床病理学意义。方法 采用逆转录-聚合酶链反应(reverse transcription-polymerase chainreaction,RT-PCR)法,蛋白质印迹法(western blot,WB)和免疫组织化学ENVISION法分别检测20例肝癌组织,19例肝硬化组织和12例对照肝组织中Mcl-1的表达,并分析其表达与肝癌临床病理学特征的关系。结果 Mcl-1 mRNA相对表达强度在对照组、肝硬化组和肝癌组中分别为0.52±0.17,3.46±1.7,3.65±2.93,其中肝癌组及肝硬化组分别与对照组间比较,差异均有统计学意义(t=7.925,5.334,P<0.05)。Mcl-1蛋白相对表达量在肝硬化组(0.51±0.35)和肝癌组(0.75±0.36)均显著高于对照组(0.21±0.19)(t=5.526和6.355,P<0.05)。肝癌组Mcl-1的阳性表达率为55.00%(11/20),显著高于对照组33.33%(4/12)(t=7.835,P<0.05),Mcl-1蛋白阳性表达与肿瘤有无坏死和TNM分期有关(χ2=4.201,P<0.05)。结论Mcl-1基因及蛋白在肝癌组、肝硬化组和对照肝组织中的表达存在差异,可能参与了肝硬化的发生、发展及向肝癌的恶性转化。
Abstract:
Objective To investigate the expression and significance of myeloid cell leukemia-1(Mcl-1)gene and protein in HepatocellularCarcinoma(HCC).Methods The expression of Mcl-1 was detected respectively by Reverse Transcription-Polymerase Chain Reaction(RT-PCR),Western blot and ENVISION immunohistochemistry in 20 HCC specimens,19 livercirrhosis(LC)specimens,and 12 control ones.Their relationship with clinical and pathological characteristics of HCC was investigated.Results The expression of Mcl-1 mRNA in the control group,LC group and HCC group was 0.52±0.17,3.46±1.7,3.65±2.93,respectively.The level in HCC and LC group was statistically different compared with the control group,respectively(t=7.925,5.334,P<0.05).The relative expression of Mcl-1 protein in LC group(0.51±0.35)and HCC group(0.75±0.36)were significantly higher than that in the control group(0.21±0.19)(t=5.526,6.355,P<0.05).The positive expression rate of Mcl-1 in HCC group was 55.00%(11/20),significantly higher than that in the control group 33.33%(4/12)(t=7.835,P<0.05).The positive expression of Mcl-1 was related to tumor necrosis and TNM staging(χ2=4.201,P<0.05).Conclusion Mcl-1 gene and protein are differentially expressed in HCC,LC and the control,which may be involved in the occurrence,development and malignant transformation ofHCC.

参考文献/References:

[1] Germano D,Daniele B.Systemic therapy of hepatoce-llular carcinoma:current status and future perspectives[J].World Journal of Gastroenterology,2014,20(12):3087-3099.
[2] 张建忠,朱建云,季学军.肝癌诊断的研究进展[J].现代检验医学杂志,2012,27(3):22-25. Zhang JZ,Zhu JY,Ji XJ.Research progress in diagnosis of hepatocellular carcinoma[J].J Mod Lab Med,2012,27(3):22-25.
[3] Takayama T. Surgical treatment for hepatocellular carcinoma[J].Jpn JClin Oncol,2011,41(4):447-454.
[4] 李保全,赵宏伟,白雪峰.肝硬化合并小肝癌与肝硬化再生结节多层螺旋CT灌注成像分析[J].实用医药杂志,2014,31(11):1000-1001. Li BQ,Zhao HW,Bai XF.Liver cirrhosis combined with small hepatocellular carcinoma and the regenerative nodules of liver cirrhosis in multislice CT perfusion imaging analysis[J].Practical Journal of Medicine & Pharmacy,2014,31(11):1000-1001.
[5] Quinn BA,Dash R,Azab B,et al.Targeting Mcl-1 for thetherapy of cancer[J].Expert Opin Investig Drugs,2011,20(10):1397-1411.
[6] 邢传平,刘 斌,董 亮.免疫组织化学标记结果的判断方法[J].中华病理学杂志,2001,30(4):318. Xing CP,Liu B,Dong L.Method for judging the results of immunohistochemistry[J].Chinese Journal of Pathology,2001,30(4):318.
[7] Whitsett TG,Mathews IT,Cardone MH,et al.Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response[J].MolCancer Res,2014,12(4):550-559.
[8] Abulwerdi F,Liao C,Liu M,et al.A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth in vitro and in vivo[J].Mol Cancer Ther,2014,13(3):565-575.
[9] Akagi H,Higuchi H,Sumimoto H,et al.Suppression of myeloid cell leukemia-1(Mcl-1)enhances chemotherapy-associated apoptosis in gastric cancer cells[J].Gastric Cancer,2013,16(1):100-110.
[10] Wuillème-Toumi S, Robillard N, Gomez P,et al.Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.Leukemia[J].Leukemia,2005,19(7):1248-1252.
[11] Lee WS,Park YL,Kim N,et al.Myeloid cell leu-kemia-1 is associatedwith tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer[J].Am J Cancer Res,2014,5(1):101-113.
[12] Liu H,Peng HW,Cheng YS,et al.Stabilization and enhancement of the antiapoptotic activity of Mcl-1 by TCTP[J].Mol Cell Biol,2005,25(8):3117-3126.
[13] 杨 威,胡虞乾,杨红杰,等.Mcl-1在肝硬化和肝癌组织中的表达及临床意义[J].华夏医学,2013,26(6):1052-1056. Yang W,Hu YQ,Yang HJ,et al.Expression and clinical significance of myeloid cell leukemia sequence-1 in liver cirrhosis and hepatocellular carcinoma[J].Acta Medicinae Sinica,2013,26(6),1052-1056.
[14] 孙凤娥,方 浩.Mcl-1蛋白的结构、功能及其抑制剂的研究进展[J].中国医药工业杂志,2013,44(3),296-302. Sun FE,Fang H.Progress in research of structure,function and inhibitorsof Mcl-1 protein[J].Chinese Journal of Pharmaceuticals,2013,44(3),296-302.

相似文献/References:

[1]申 旺,杨文丽,叶丽燕,等.血清唾液酸在原发性肝癌和转移性肝癌诊断中的临床价值[J].现代检验医学杂志,2015,30(01):140.[doi:10.3969/j.issn.1671-7414.2015.01.042]
　SHEN Wang,YANG Wen-li,YE Li-yan,et al.Clinical Value of Serum Sialic Acid Detection for Diagnosis in Primary Hepatic Carcinoma and Metastatic Hepatic Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(03):140.[doi:10.3969/j.issn.1671-7414.2015.01.042]
[2]周淑燕,卓传尚,柳丽娟,等.PIVKA-II和AFP联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2017,32(01):69.[doi:10.3969/j.issn.1671-7414.2017.01.019]
　ZHOU Shu-yan,ZHUO Chuan-shang,LIU Li-juan,et al.Clinical Value of Serum PIVKA-lI and AFP Detection for Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(03):69.[doi:10.3969/j.issn.1671-7414.2017.01.019]

备注/Memo

备注/Memo:
作者简介:李 峰(1977-),男,硕士,副主任技师,研究方向:消化道肿瘤,E-mail:willim118@hotmail.com。 通讯作者:张 弘(1955-),男,硕士,主任技师,研究方向:消化道肿瘤,E-mail:zhangh111@sina.com。
更新日期/Last Update: 2016-06-25